Clinical Features and Treatment Outcomes among Children with Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A 20-Year Study in a Tertiary Referral Hospital

Table 4

Long-term sequel according to diagnosis and treatment.

	Diagnosis			Treatment
	SJS, N = 20	Overlap-TEN, N = 16	P value	Supportive care, N = 8	Systemic treatment, N = 28	P value
Long-term skin sequel, N (%)
Dyspigmentation	4 (20.0)	14 (87.5)	<0.001	3 (37.5)	15 (53.6)	0.423
Xerosis	1 (5.0)	0	0.364	1 (12.5)	0	0.058
Nail loss	0	1 (6.2)	0.257	0	1 (3.6)	0.588
Long-term eye sequel, N (%)
Dry eye	4 (20.0)	6 (37.5)	0.244	4 (50.0)	6 (21.6)	0.112
Corneal scar	0	4 (25.0)	0.018	1 (12.5)	3 (10.7)	0.887
Keratopathy	0	3 (18.8)	0.043	2 (25.0)	1 (3.6)	0.053
Subconjunctival fibrosis	0	1 (6.2)	0.257	0	1 (3.6)	0.588
Long-term GI sequel, N (%)
Transaminitis
Less than 3 m	2 (10.0)	5 (31.2)	0.109	2 (25.0)	5 (17.9)	0.653
More than 3 m	0	1 (6.2)	0.257	0	1 (3.6)	0.588

Significant values are shown in bold.